Back to Search
FREDERICK HEBERT, MD
MD
Child & Adolescent Psychiatry Physician
NPI: 1366472540Individual
Specialties, Licenses & Credentials
Child & Adolescent Psychiatry PhysicianPrimary
Psychiatry & Neurology — Child & Adolescent Psychiatry
Code: 2084P0804X
17062(CO)
Research & Publications (18)
Quantum Monte Carlo study of an interaction-driven band-insulator-to-metal transition.
PMID 17358793·Phys Rev Lett·2007
8-other
Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA.
PMID 15162380·Prostate·2004
7-preclinical
Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
PMID 14633721·Cancer Res·2003
7-preclinical
Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
PMID 12684683·Int J Oncol·2003
4-observational
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
PMID 11830533·Cancer Res·2002
7-preclinical
Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.
PMID 11891317·Proc Natl Acad Sci U S A·2002
7-preclinical
Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
PMID 12111694·Prostate·2002
7-preclinical
Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth.
PMID 11564700·Endocrinology·2001
7-preclinical
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
PMID 11290438·Eur J Cancer·2001
7-preclinical
Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
PMID 11555603·Clin Cancer Res·2001
7-preclinical
Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
PMID 11485826·Cancer Lett·2001
7-preclinical
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours.
PMID 10741306·Eur J Cancer·2000
7-preclinical
Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
PMID 10850448·Cancer Res·2000
7-preclinical
Secondary enuresis associated with obstructive sleep apnea.
PMID 10673821·J Am Acad Child Adolesc Psychiatry·2000
5-case
Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
PMID 10881027·Prostate·2000
7-preclinical
Human ovarian cancers express somatostatin receptors.
PMID 11061491·J Clin Endocrinol Metab·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1056 E 19TH AVE, B130
DENVER, CO 80218 - Phone
- (303) 861-6200
Quick Facts
- NPI
- 1366472540
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 18
Are you this provider?
Claim Your Profile